Five-Year Survival after Second-Line Cisplatin-Based Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
- 31 March 1998
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 68 (3) , 267-273
- https://doi.org/10.1006/gyno.1998.4940
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinomaCancer, 1994
- Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancerCancer, 1994
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958